The Pharma Legal Handbook: Germany

Germany is Europe's largest pharmaceutical market and the reference pricing benchmark for much of the continent. The early benefit assessment process under AMNOG is one of the most consequential pricing and reimbursement mechanisms in the world, with the outcomes of German AMNOG assessments directly influencing pricing negotiations in multiple other European markets.

The Pharma Legal Handbook: Germany provides a comprehensive reference for pharmaceutical regulation in Germany. It covers product authorisation, the AMNOG early benefit assessment process, statutory health insurance reimbursement negotiations, clinical trial requirements, pharmacovigilance obligations, manufacturing and GMP requirements, marketing and advertising rules, parallel imports, and patent and trademark protection.

Germany's regulatory environment is demanding and the AMNOG process is complex and consequential. The commercial implications of getting it wrong extend beyond the German market itself. This handbook gives regulatory affairs, market access, legal and commercial teams the country-specific knowledge they need.

If legal handbook content is updated, you will receive an updated PDF free for up to one year after purchase.